Article
New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).
New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).
Under the deal with Quark Biotech Inc., Pfizer will develop the gene, called RTP-801, and molecules that modify it, to treat wet AMD. Financial terms of the deal were not disclosed.
Quark Biotech, a Fremont, CA-based company with research facilities in Fremont and Israel, combines gene silencing and DNA microarray technology to identify target genes and proteins related to the cause or progression of a disease. It is working on potential treatments for dyslipidemia and fibrotic and ischemic diseases of the eye and kidneys, including diabetic retinopathy.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.